<DOC>
	<DOCNO>NCT02042612</DOCNO>
	<brief_summary>Describing pharmacokinetic model 48-h sevoflurane sedation obese ICU patient</brief_summary>
	<brief_title>Pharmacokinetic Study 48-hour Sevoflurane Inhalation Using Disposable Delivery System ( AnaConDa© ) Obese ICU Patients</brief_title>
	<detailed_description>Prospective clinical monocentric study ICU sedate ventilated obese patient sevoflurane 48 h AnaConda® system , establish pharmacokinetic model sévoflurane metabolite ( hydroxyfluroisopropanol , fluoride )</detailed_description>
	<mesh_term>Sevoflurane</mesh_term>
	<criteria>Adult patient ventilate 48 h Stable respiratory hemodynamic condition Consent patient family Arterial line BMI &gt; 30 Acute kidney injury BMI &lt; 30 Sevoflurane anaphylaxia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Sevoflurane</keyword>
	<keyword>Obesity</keyword>
	<keyword>Sedation</keyword>
	<keyword>ICU patient</keyword>
</DOC>